Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | HRAS act mut |
| Therapy | Encorafenib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| HRAS act mut | Advanced Solid Tumor | resistant | Encorafenib | FDA contraindicated | Actionable | Braftovi (encorafenib) is not indicated for patients who have developed non-cutaneous, RAS-mutant malignancies (FDA.gov). | detail... detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| FDA.gov | Full reference... | |
| Braftovi (encorafenib) FDA Drug Label | Full reference... |